跳轉至內容
Merck
全部照片(2)

Key Documents

855675P

Avanti

16:0 Lyso PC

Avanti Research - A Croda Brand

同義詞:

1-十六烷酰基-sn-甘油-3-磷酸胆碱;PC(16:0/0:0)

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C24H50NO7P
CAS號碼:
分子量::
495.63
分類程式碼代碼:
51191904
NACRES:
NA.25

描述

1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine

化驗

>99% (LPC; may contain up to 10% of the 2-LPC isomer, TLC)

形狀

powder

包裝

pkg of 1 × 1 g (855675P-1g)
pkg of 1 × 200 mg (855675P-200mg)
pkg of 1 × 25 mg (855675P-25mg)
pkg of 1 × 500 mg (855675P-500mg)

製造商/商標名

Avanti Research - A Croda Brand

運輸包裝

dry ice

儲存溫度

−20°C

SMILES 字串

O[C@](COP([O-])(OCC[N+](C)(C)C)=O)([H])COC(CCCCCCCCCCCCCCC)=O

InChI

1S/C24H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)30-21-23(26)22-32-33(28,29)31-20-19-25(2,3)4/h23,26H,5-22H2,1-4H3/t23-/m1/s1

InChI 密鑰

ASWBNKHCZGQVJV-HSZRJFAPSA-N

應用


  • Microbubble-Mediated Drug Delivery: The role of 16:0 Lyso PC in the development of microbubble technologies for drug delivery systems emphasizes its potential in pharmaceutical formulations, enhancing the efficiency of targeted therapy applications, particularly in cancer treatment (Aron et al., 2019).

  • Photodynamic Therapy for Glioma: Research involving 16:0 Lyso PC in the context of biohybrid systems for light-activatable treatments showcases its application in medical therapies, particularly for treating challenging conditions like glioma through photodynamic therapy, underlining its potential in enhancing clinical outcomes (Inglut et al., 2019).

包裝

20 mL 透明玻璃螺纹口小瓶(855675P-1g)
20 mL 透明玻璃螺纹口小瓶(855675P-500mg)
5 mL 棕色玻璃螺纹口样品瓶(855675P-200mg)
5 mL 棕色玻璃螺纹口样品瓶(855675P-25mg)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Xinyuan Li et al.
Redox biology, 28, 101373-101373 (2019-11-16)
It has been shown that anti-inflammatory cytokines interleukin-35 (IL-35) and IL-10 could inhibit acute endothelial cell (EC) activation, however, it remains unknown if and by what pathways IL-35 and IL-10 could block atherogenic lipid lysophosphatidylcholine (LPC)-induced sustained EC activation; and
Takafumi Enomoto et al.
Langmuir : the ACS journal of surfaces and colloids, 34(3), 750-755 (2017-10-06)
A major goal of synthetic biology is the development of rational methodologies to construct self-assembling non-natural membranes, which could enable the efficient fabrication of artificial cellular systems from purely synthetic components. However, spatiotemporal control of artificial membrane formation remains both
Li V Yang et al.
Blood, 105(3), 1127-1134 (2004-09-24)
G2A is a G-protein-coupled receptor (GPCR) involved in immune regulation. Previous studies have shown that lysophosphatidylcholine (LPC), a bioactive lipid associated with atherosclerosis and autoimmunity, acts through G2A to induce diverse biologic effects. Production of LPC during cell apoptosis serves
Caius G Radu et al.
Proceedings of the National Academy of Sciences of the United States of America, 101(1), 245-250 (2003-12-19)
G2A is an immunoregulatory G protein-coupled receptor predominantly expressed in lymphocytes and macrophages. Ectopic overexpression studies have implicated G2A as a receptor for the bioactive lysophospholipid, lysophosphatidylcholine (LPC). However, the functional consequences of LPC-G2A interaction at physiological levels of receptor
Anthony J Valente et al.
Free radical biology & medicine, 70, 117-128 (2014-02-25)
Oxidized low-density lipoprotein (oxLDL) induces endothelial cell death through the activation of NF-κB and AP-1 pathways. TRAF3IP2 is a redox-sensitive cytoplasmic adapter protein and an upstream regulator of IKK/NF-κB and JNK/AP-1. Here we show that oxLDL-induced death in human primary

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務